PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Institut Regional DU Cancer DE Montpellier (icm)

USPTO PatentsView assignee record - 16 granted patents across 7 technology areas, active 2017–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Explore the portfolio See the ranking
16
Total patents granted
7
CPC technology areas
12.7
Avg claims per patent
+67%
5-year filing velocity

The verdict

Institut holds 16 US patents across 7 technology areas, rank #17,775 of 50,000 tracked assignees.

#17,775
of 50,000 US assignees by volume
Top 67%
by Innovation Score (30.1/100)
12.7
avg claims per patent
+67%
filing velocity, last 5 yrs

Portfolio overview

Institut Regional DU Cancer DE Montpellier (icm) has been granted 16 US utility patents between 2017 and 2024, placing Institut Regional DU Cancer DE Montpellier (icm) at rank #17,775 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.7 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Institut Regional DU Cancer DE Montpellier (icm) is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 30.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 10 grants, compared with 6 in the 2015–2019 window, a +67% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Institut Regional DU Cancer DE Montpellier (icm)'s 12.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Institut Regional DU Cancer DE Montpellier (icm) against peers pursuing similar technology classes.

How does Institut compare?

Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀

patents

What this shows Institut holds 16 patents, placing it at rank #17,775 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Institut's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

30 Top 67% higher than 33% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2024

0.511.522.533.5 20172018201920202021202220232024 1
USPTO utility patent grants by year · 2017–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table
Institut Regional DU Cancer DE Montpellier (icm) patent grants by year, 2015–2025
Year Patents Granted Share of Period
2017 1 6.3%
2018 3 18.8%
2019 2 12.5%
2020 3 18.8%
2021 3 18.8%
2022 1 6.3%
2023 2 12.5%
2024 1 6.3%

Which technologies does Institut Regional DU Cancer DE Montpellier (icm) patent most?

Top 7 of 7 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Accelerating

Where it ranks

Overall rank by patents

#17,775

Across all tracked assignees

Innovation Score

30.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Institut Regional DU Cancer DE Montpellier (icm) hold?
Institut Regional DU Cancer DE Montpellier (icm) holds 16 US granted patents filed between 2017 and 2024, spanning 7 technology areas.
What is Institut Regional DU Cancer DE Montpellier (icm)'s Innovation Score?
Institut Regional DU Cancer DE Montpellier (icm) has an Innovation Score of 30.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Institut Regional DU Cancer DE Montpellier (icm) focus on?
Institut Regional DU Cancer DE Montpellier (icm)'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 11 patents. The company has filed patents in 7 CPC subclasses total.
Is Institut Regional DU Cancer DE Montpellier (icm)'s patent filing rate increasing or decreasing?
Institut Regional DU Cancer DE Montpellier (icm)'s recent filing velocity is +67% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Institut Regional DU Cancer DE Montpellier (icm)'s patents?
Institut Regional DU Cancer DE Montpellier (icm)'s patents average 12.7 claims each. This falls within the standard range, providing solid legal coverage.
How is the Institut Regional DU Cancer DE Montpellier (icm) patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Guides to patent portfolio analysis

How Innovation Score Works

Understand the four dimensions behind the composite score
How to Read Patent Data

Plain-English guide to CPC codes, claims, and metrics
Patent Moat Analysis

How companies use patents as competitive barriers

How to use this portfolio

Institut's 16 grants land it in the top 67% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Institut ranks #17,775 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

A61P technology

Institut Regional DU Cancer DE Montpellier (icm)'s primary CPC class, all holders and yearly trends
Top 50 patent holders

See where Institut Regional DU Cancer DE Montpellier (icm) ranks among the largest US patent assignees
All technology classes

Browse every CPC technology area by patent activity
How the score works

The four dimensions behind the Innovation Score

Related

All companies → | All technologies → | Rankings →
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.